Zofran Lawsuit Alleges Baby’s Cleft Palate, Clubfoot, And Respiratory Distress Due To Drug Exposure

January 04, 2016 – – ZofranLegal.com reports on a lawsuit filed against Zofran manufacturer GlaxoSmithKline by an Arkansas woman. The lawsuit alleges her unborn son to have developed multiple birth defects including cleft palate, clubfoot, and respiratory distress syndrome due to exposure to anti-nausea drug Zofran.

The fetus was exposed to the drug while in the womb when the mother was prescribed Zofran for morning sickness, and took it throughout her first trimester. After being exposed to the drug, her son was born in 2007, and required multiple surgeries in attempt to repair his congenital birth defects.

Further details of the mother’s lawsuit explain that she used anti-nausea drug Zofran during just one of her 3 pregnancies. That particular pregnancy was the only one to result in birth defects. Women most commonly experience morning sickness during their first trimester. Coincidentally, this is also a time when the fetus does much of its limb, mouth, and heart tissue development.

Unfortunately, this mother is not the only parent to claim that their child developed defects because of Zofran exposure. Across the nation, many families have now filed lawsuits against GlaxoSmithKline making very similar allegations.

The mounting Zofran birth defect lawsuits claim that exposure to the drug while in utero caused infants to develop clubfoot, cleft lip and palate, transposition of the greater vessels, tetralogy of fallot, ventricular septal defect and atrial septal defect, kidney defects, and respiratory distress. In certain cases, these defects have been fatal ones, and parents have lost their children.

Zofran birth defect lawsuits filed in federal court have now been consolidated to form multidistrict litigation number 2657. Plaintiffs frequently note that Zofran was never FDA-approved to treat pregnant women, or tested for safety on these individuals and their unborn children. Instead, the FDA approved the drug to treat those suffering from nausea and vomiting after undergoing chemotherapy, radiation, or anesthesia.

Despite this specific approval, however, pharmaceutical conglomerate GlaxoSmithKline chose to market the drug “off-label” to pregnant women and Ob/Gyns across the U.S. as a treatment for morning sickness.

The attorneys at Monheit Law are working to help ensure that everyone affected by Zofran will have the opportunity to fully explore their legal rights. Women who were prescribed the drug while pregnant and who subsequently gave birth to children with congenital defects may be entitled to compensation. Monheit Law is currently offering free consultations to those affected.

To request more information, or ask questions at any time, please contact Attorney Michael Monheit by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60006899